Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pivot, X.
Right arrow Articles by Milano, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pivot, X.
Right arrow Articles by Milano, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1578-1586, 2003
© 2003 European Society for Medical Oncology

Original Paper

Phase I and pharmacokinetic study of the association of capecitabine–cisplatin in head and neck cancer patients

X. Pivot1, E. Chamorey2, E. Guardiola1, N. Magné2, A. Thyss2, J. Otto2, B. Giroux3, Z. Mouri3, M. Schneider3 and G. Milano2,+

1 Centre Hospitalier Jean Minjoz, Department of Medical Oncology, Besançon; 2 Centre Antoine Lacassagne, Oncopharmacology Unit, Nice; 3 Roche Pharmaceuticals, Neuilly sur Seine, France

Received 19 December 2002; revised 25 April 2003; accepted 17 June 2003

The combination of cisplatin and 5-fluorouracil (5-FU) is considered to be the standard treatment in induction chemotherapy for patients with squamous cell carcinoma of the head and neck. Capecitabine (Xeloda®) is an oral fluoropyrimidine that is preferentially activated at the tumoral level, exploiting the higher thymidine phosphorylase activity in tumoral tissue. This phase I trial was conducted in patients with locally recurrent or metastatic head and neck carcinoma. The treatment plan included cisplatin on day 1 every 21 days, followed by capecitabine twice daily from day 2 to day 15, with a 1-week rest period. Pharmacokinetic investigations concerned plasma measurement of unchanged capecitabine, 5'-deoxy-5-fluorocytidine, 5'-doxifluridine and 5-FU using an optimized high performance liquid chromatography method, and cisplatin measurement in plasma using a limited sampling procedure. Twenty-one patients were included (mean age 61 years, range 46–76 years). Dose (mg/m2) increments for cisplatin and capecitabine (b.i.d.), respectively, were as follows: level 1, 80 and 1000 (three patients); level 2, 100 and 1000 (12 patients); and level 3, 100 and 1125 (five patients). Dose-limiting toxicities occurring during the first cycle (grade >=3) were observed on level 2 (one patient with diarrhea, nausea, vomiting, hand–foot syndrome, one toxic death due to renal failure and neutropenia, one patient with neutropenia) and on level 3 (one patient with diarrhea, one patient with hand–foot syndrome and one patient with neutrothrombocytopenia). Due to delayed side-effects, 14 patients (67%) had repeated cycles every 28 days instead of 21 days as initially planned. Objective response was obtained in seven patients (three complete responses and four partial responses). There was no evidence of pharmacokinetic–pharmacodynamic relationships with the drugs and metabolites investigated. Combination of capecitabine and cisplatin is feasible, with a very promising response rate. The recommended doses for further phase II studies are those of level 2 with cisplatin 100 mg/m2 on day 1 and capecitabine 1000 mg/m2 b.i.d. on days 1–14, every 28 days.

Key words: capecitabine, cisplatin, head and neck cancer, pharmacokinetic study, phase I clinical trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
C. Y. THOMAS, P. READ, G. PETRONI, J. REIBEL, and P. A. LEVINE
Phase I Study of Capecitabine, Carboplatin and Intensity-modulated Radiation Therapy for Head and Neck Cancer
Anticancer Res, July 1, 2009; 29(7): 2869 - 2873.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. S. Lee, J.-L. Lee, M.-H. Ryu, H. M. Chang, T. W. Kim, H.-J. Kang, W. K. Kim, J. S. Lee, and Y.-K. Kang
Combination Chemotherapy with Capecitabine (X) and Cisplatin (P) as First Line Treatment in Advanced Gastric Cancer: Experience of 223 Patients with Prognostic Factor Analysis
Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 30 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Largillier, M.-C. Etienne-Grimaldi, J.-L. Formento, J. Ciccolini, J.-F. Nebbia, A. Ginot, M. Francoual, N. Renee, J.-M. Ferrero, C. Foa, et al.
Pharmacogenetics of capecitabine in advanced breast cancer patients.
Clin. Cancer Res., September 15, 2006; 12(18): 5496 - 5502.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. G. Fakih, P. J. Creaven, N. Ramnath, D. Trump, M. Javle, S. Strychor, T. V.W. Repinski, B. A. Zamboni, J. K. Schwarz, R. A. French, et al.
Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors
Clin. Cancer Res., August 15, 2005; 11(16): 5942 - 5949.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bourhis
New approaches to enhance chemotherapy in SCCHN
Ann. Onc., January 1, 2005; 16(suppl_6): vi20 - vi24.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.